• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    11/13/25 10:06:55 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email
    false 0001494891 0001494891 2025-11-10 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, DC 20549

    ____________________

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the 

    Securities Exchange Act of 1934 

    Date of Report (Date of earliest event reported): November 10, 2025

     

    SENSUS HEALTHCARE, INC. 

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-37714

     

    27-1647271

    (State of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
             

    851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida

     

    33487

    (Address of principal executive offices)   (Zip Code)

     

    Registrant's telephone number, including area code: (561) 922-5808

    _________________________________________________

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.01 per share   SRTS   Nasdaq Stock Market, LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    SENSUS HEALTHCARE, INC.

     

    FORM 8-K

    CURRENT REPORT

     

    ITEM 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    (d)

     

    On November 10, 2025, the Board of Directors (the “Board”) of Sensus Healthcare, Inc. (the “Company”) appointed Eric Sachetta as a Class II director of the Company for a term expiring at the Company’s annual meeting in 2026. Mr. Sachetta fills a vacancy resulting from the death of William McCall.

     

    Mr. Sachetta, age 37, is Chief Wealth Services Officer of Sachetta, LLC, a financial advisory firm founded by Mr. Sachetta. In that role, his responsibilities include leading and managing the firm’s financial advisory division and overseeing all wealth management operations and advisor development. Before assuming his current position in 2022, he held other positions with the firm from 2016. Mr. Sachetta’s previous employment included serving as a leadership speaker and author and as a district manager of a marketing organization. He is a Certified Financial Planner® and holds other licenses and certifications. Mr. Sachetta received a bachelor’s degree in Corporate Finance and Accounting from Bentley University.

     

    There are no arrangements or understandings between Mr. Sachetta and any other persons pursuant to which he was elected, nor does he have any direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Securities and Exchange Commission Regulation S-K. As a director of the Company, Mr. Sachetta is expected to receive the same compensation for service as a director as is provided to other non-employee directors of the Company on a pro-rata annual basis. The Board has determined that Mr. Sachetta is an independent director within the meaning of Rule 5605(a)(2) as set forth in the listing standards of The NASDAQ Stock Market, LLC. Mr. Sachetta has been appointed as a member of the Audit Committee of the Board.

     

    On November 12, 2025, the Company issued a press release announcing Mr. Sachetta’s election. The press release is filed as an exhibit to this Report. The press release shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    99.1Press Release dated November 12, 2025.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)
      

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SENSUS HEALTHCARE, INC.
       
    Date:       November 13, 2025 By: /s/ Javier Rampolla  
        Javier Rampolla
        Chief Financial Officer

     

     

     

    EXHIBIT INDEX

       
    Exhibit
    Number
    Description
    99.1 Press Release, dated November 12, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

    Get the next $SRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

    New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT® codes for office-based SRT and the growing commercial opportunity the Company now faces Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel® software and rela

    11/14/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    New insider Sachetta Eric claimed ownership of 132,706 shares (SEC Form 3)

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 1:55:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $100,750 worth of shares (25,000 units at $4.03), increasing direct ownership by 2% to 1,200,293 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/19/25 9:34:10 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    SEC Filings

    View All

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/13/25 10:06:55 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Sensus Healthcare Inc.

    10-Q - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/12/25 2:56:42 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    11/6/25 4:15:45 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Sensus Healthcare with a new price target

    Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

    1/31/25 9:07:11 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on Sensus Healthcare with a new price target

    Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

    11/15/24 8:09:06 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

    HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

    3/3/22 6:32:52 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Financials

    Live finance-specific insights

    View All

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the cal

    10/23/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Second Quarter 2025 Financial Results

    Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited the quarter with $22.2 million in cash and no debt Proposed Physician Fee Schedule expected to favorably impact adoption of SRT technology beginning in 2026 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the

    8/7/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

    Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

    5/1/25 4:30:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Announces Retirement of Director Samuel O'Rear

    BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv

    2/1/24 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/6/24 12:27:47 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/10/23 11:51:22 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/7/22 8:30:08 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care